13281

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mair Stop Patent Application Attv. Dkt.: 620-301 Commissioner for Patents Date: April 13, 2004 P.**⊡**Box 1450 Al Andria, VA 22313-1450 Attached for filing is the patent application of: Inventor: DAVIS et al USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC FIBROSIS (CF) AND Entitled: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) and including attachments as noted below: Newly executed Declaration, \overline{\times} Copy of Declaration from prior application, \overline{\times} Abstract Please **delete** the following inventors in the continuation/division/continuation-in-part application: **Deleted** persons: 38 pages of specification and claims (including 10 numbered claims), and sheets of accompanying drawing/s for Figures 1 - 9. Record the attached assignment to and return to the undersigned. Attached is a Power of Attorney. Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications: Day/Month/Year Filed **Application Number** Country 0016441.8 Great Britain 04/July/2000 , respectively, the entire content of which is hereby incorporated by reference in this application... Certified copy(ies) of foreign application(s) is/are attached. Certified copy(ies) filed on August 3, 2001 in prior appln. no. 09/897,412 filed July 3, 2001 This application claims the benefit of Provisional Application No. . filed . the entire content of which is hereby incorporated by reference in this application. This application is a __ continuation/_ division/_ continuation-in-part of Application No. 09/897,412, filed July 3, 2001, the entire content of which is hereby incorporated by reference in this application. The prior application is assigned to Pharmagene Laboratories Ltd., Hertfordshire, United Kingdom. It is hereby requested that the Examiner consider the art cited in the parent application by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached. Applicant claims "small entity" status.

"Small entity" statement attached. Please enter the attached preliminary amendment prior to calculation of filing fee: \boxtimes Also attached:
☐ Information Disclosure Statement; ☐ Non-Publication Request; ☐ Nucleotide and/or Amino Acid Sequence Submission; Statement deleting Inventor(s) named in prior application; Statement deleting Inventor(s) Nine (9) sheets formal drawings (Figs. 1-9); Request & copy of Sequence Listing filed 11/23/2001 FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HEREWITH CANCELED Basic Filing Fee 770.00 - 20 (at least 20) = 0.00 Total effective claims 10 0 x \$ 18.00 \$ - 3 (at least 3) = 4 x \$ 86.00 86.00 Independent claims 1 If any proper multiple dependent claims now added for first time, add \$290.00 (ignore improper) 0.00 SUBTOTAL 856.00 If "small entity," then enter half (1/2) of subtotal and subtract 0.00)SECOND SUBTOTAL 856.00 Assignment Recording Fee (\$40.00) 0.00 **TOTAL FEE ENCLOSED \$** 856.00 Any future submission requiring an extension of time is hereby stated to include a petition for such time extension. The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached. Correspondence Address: **NIXON & VANDERHYE P.C.** By Atty: B. J. Sadoff, Reg. No. 36,663 23117 Customer Number: Telephone: (703) 816-4000 Facsimile: (703) 816-4100 BJS:pp

Signature: